Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00517582 · ClinicalTrials.gov registry record · Phase 1
Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema
A Phase 1 study, sponsored by Vanderbilt University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT00517582: Clinical Trial Phase 1 study, sponsored by Vanderbilt University.
NCT00517582 is a Phase 1 study that was terminated before completion, run by Vanderbilt University. The registered enrollment target is 13 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00517582, a Phase 1 study, was terminated before completion, sponsored by Vanderbilt University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
Individuals with heart disease or high blood pressure are often prescribed angiotensin converting enzyme (ACE) inhibitors to treat their disease. However, the use of ACE inhibitors can be associated with angioedema, a rare but life-threatening condition that causes swelling of the face and other body parts. This study will evaluate the effectiveness of the drug HOE-140 at decreasing symptoms of angioedema in people taking ACE inhibitors who develop the condition.
Interventions
- OTHER Placebo
- DRUG HOE-140
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2007-09 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Why NCT00517582 stopped before completion
NCT00517582 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00517582 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00517582 about?
NCT00517582 is a clinical study titled "Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema". Individuals with heart disease or high blood pressure are often prescribed angiotensin converting enzyme (ACE) inhibitors to treat their disease. However, the use of ACE inhibitors can be associated with angioedema, a rare but life-threatening condition that causes swelling of the face and other bod...
What is the current status of trial NCT00517582?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2007-09. Estimated completion is 2015-12.
What interventions are being tested in trial NCT00517582?
The interventions under investigation include: Placebo (OTHER), HOE-140 (DRUG).
Who is sponsoring clinical trial NCT00517582?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00517582's enrollment target sits among peer trials
13 1847th of 2000 higher than 149 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia